Sight Sciences Inc (SGHT) Enterprise Value to EBITDA Ratio
The EV/EBITDA price dynamics history for Sight Sciences, Inc. (SGHT) on the GURU.Markets platform is 0.00, confirming the brand's authority in ocular microsurgery due to the reliability of OMNI systems. Average cash flow stability is driven by the expansion of ophthalmology products and investments in scaling. An efficient polymer supply chain and strategic inventory management ensure that clinics receive necessary medical devices promptly.
Comprehensive metric breakdowns and analytics for sightsciences.com (SGHT)
- current price and projected stock value:
- market capitalization details:
- business book valuation details:
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Sight Sciences, Inc.|SGHT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Sight Sciences|SGHT - Company Total Debt|Debts to Book Capitalization Sight Sciences Inc|SGHT - Long-Term Debt|Company Short-Term Debts Sight Sciences, Inc.|Quick Ratio sightsciences.com
- financial results and valuation multiples details:
SGHT - Net Financial Result|Projected Future Earnings Sight Sciences, Inc.|SGHT - Price to Earnings Ratio|Forward P/E Multiple Sight Sciences, Inc.|SGHT - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sight Sciences Inc|SGHT - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Sight Sciences, Inc.|SGHT - Earnings per share for the trailing year|Quarterly EPS earnings growth sightsciences.com|SGHT - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Sight Sciences, Inc.
- revenue and sales details:
Analysis of all company metrics:Sight Sciences, Inc SGHT
This indicator compares the total enterprise value, including net debt, with its operating profit before depreciation and amortization. Analyzing the EV/EBITDA ratio allows for the isolation of tax regimes and debt loads from the actual efficiency of assets. This chart's trend helps identify the undervaluation of Sight Sciences, Inc. (SGHT) against the backdrop of market cycles. For biopharmaceuticals, such a metric is critical, as it reflects capital resilience to sanction risks within supply chains.
Competitor analysis
EV/EBITDA Multiple BSX (Boston Scientific Inc)|Total Company Value to Operating Income Before Depreciation Ratio Edwards Lifesciences Inc. (EW)|RMD: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio PODD|ZBH: EV/EBITDA Multiple|Company Value to EBITDA The Cooper Companies, Inc. (COO)|ALGN (Align Technology Inc) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation GMED (NuVasive)|Enterprise Value to EBITDA Ratio TMDX (TransMedics)|ATEC (atecspine.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artivion AORT|ENOV - Enterprise Value to EBITDA Ratio|Integra - EV/EBITDA Multiple|Company Value to EBITDA Establishment Labs Inc|BBNX: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation IRMD|EMBC (Embecta) - EV/EBITDA Multiple|Tandem Diabetes Care Inc (TNDM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AXGN|Enterprise Value to EBITDA Ratio SI-BONE Medical SIBN|EV/EBITDA Multiple OFIX (Orthofix Medical Inc.)|EV/EBITDA Multiple bioventus.com BVS|KIDS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TMCI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SRTA (Strata Critical Medical Corp) - Enterprise Value to EBITDA Ratio|Carlsmed Medical - Business Value to Operating Income Before Depreciation|RXST (RxSight, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA ClearPoint CLPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Stereotaxis (STXS)|Neuronetics Inc. (STIM) - Enterprise Value to EBITDA Multiple|Orchestra BioMed - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Anika Therapeutics Inc. ANIK|InspireMD, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Jin Medical International ZJYL|vivani.com (VANI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio XTNT (Xtant Medical)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroOne Corp|Enterprise Value to EBITDA Ratio Modular Med (MODD)|EV/EBITDA Multiple MYO|COCH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vivos Therapeutics, Inc. VVOS|NVNO: Enterprise Value to Operating Income Before Depreciation|SINT: Enterprise Value to EBITDA Ratio|Tenon Medical Inc - Enterprise Value to Operating Income Before Depreciation Ratio|ReWalk Robotics Ltd. (LFWD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AMIX - Total Company Value to Operating Income Before Depreciation Ratio|IVF (INVO Fertility) - EV/EBITDA Multiple|Bone Biologics Corp. (BBLG) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AXNX|Biolase Inc. (BIOL) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple DYNT (Dynatronics)|Business Value to Operating Income Before Depreciation FNA|INVO: Enterprise Value to EBITDA Ratio
